CD ComputaBio provides cutting-edge software-based virtual services to empower researchers, but we do not offer free software packages.
De-Risk Your Antibody Pipeline with Predictive Intelligence
In the competitive landscape of biologics development, identifying high-affinity antibodies is no longer sufficient. A large proportion of promising antibody candidates ultimately fail—not because of lack of efficacy, but due to poor developability profiles, including instability, aggregation, immunogenicity, or manufacturability challenges.
At CD ComputaBio, our AbGenesis™ Platform delivers a next-generation AI-driven antibody developability assessment solution that enables early risk identification, multi-parameter optimization, and data-driven candidate prioritization. By integrating computational intelligence with experimental validation, we help you eliminate liabilities early, accelerate development timelines, and significantly improve clinical success rates.
Figure 1. AbGenesis™ Platform.
Why Developability is the Hidden Bottleneck in Antibody Development
Despite major advances in antibody discovery technologies, developability remains one of the most critical and under-addressed challenges in biologics pipelines.
Key Challenges in Traditional Workflows
Challenge
Impact on Drug Development
Late-stage failure due to poor stability or aggregation
High cost and wasted resources
Immunogenicity risks identified too late
Clinical trial delays or termination
Lack of predictive tools for manufacturability
Scale-up challenges and CMC risks
Iterative wet-lab screening
Time-consuming and inefficient
Single-parameter optimization strategies
Suboptimal candidate selection
Traditional workflows often rely heavily on experimental screening after candidate generation, leading to reactive problem-solving rather than proactive risk mitigation.
Our Solution: AI-Driven Developability Assessment with AbGenesis™
At CD ComputaBio, we shift developability evaluation from late-stage validation to early-stage prediction.
Our AI-powered developability assessment framework leverages multi-dimensional data, advanced machine learning models, and structural biology insights to evaluate antibody candidates across all critical parameters simultaneously.
What Makes Our Approach Different?
Predictive, not reactive: Identify risks before wet-lab investment
Multi-parameter intelligence: Evaluate all key developability factors in parallel
Data-driven prioritization: Select the best candidates with confidence
Closed-loop optimization: Continuously refine candidates using AI feedback
👉 This "Shift-Left Strategy" allows you to fail fast, optimize early, and succeed faster.
Key Developability Parameters We Evaluate
Our platform simultaneously assesses multiple critical attributes to ensure your antibody candidates are not only potent—but also developable.
Category
Parameters Assessed
AI Capability
Business Impact
Stability
Thermal stability, folding integrity
Predict structural robustness
Reduce degradation risk
Aggregation
Aggregation hotspots, surface hydrophobicity
Identify aggregation-prone regions
Improve formulation success
Immunogenicity
T-cell epitope prediction, sequence liabilities
Minimize immune response risk
Increase clinical success probability
Solubility
Solubility profile, expression behavior
Predict expression efficiency
Improve production yield
Manufacturability
Expression level, viscosity, PTM liabilities
Assess production feasibility
Reduce CMC risks
Specificity
Off-target binding, cross-reactivity
Improve target selectivity
Enhance safety profile
Unlike traditional approaches, we do not evaluate these parameters in isolation. Instead, our platform provides a balanced multi-objective optimization strategy, ensuring that improvements in one area do not compromise another.
Intelligent Optimization Strategies
If a high-affinity candidate shows a developability flaw, we don't just flag it—we fix it. Our AI-driven optimization includes:
Liability Removal: Strategically replacing amino acids that cause PTMs (Post-Translational Modifications) without losing affinity.
Humanization 2.0: Maximizing human-ness while maintaining structural stability.
Stability Engineering: Introducing salt bridges or optimizing the hydrophobic core to increase thermal stability.
Viscosity Reduction: Surface charge engineering to enable high-concentration subcutaneous delivery.
Figure 2. AI optimization strategies.
Closing the Loop: Integrated Wet-Lab Validation
To ensure real-world reliability, our AI predictions can be validated through our integrated experimental capabilities.
Expression Validation
Recombinant antibody expression
Yield and solubility assessment
Biophysical Characterization
Thermal stability (DSF)
Aggregation analysis (SEC, DLS)
Functional & Developability Validation
Binding affinity (SPR/BLI)
Immunogenicity assays
What Input Data Is Required to Start a Project?
The minimum requirement to initiate a developability assessment is:
Antibody amino acid sequences (heavy and light chains, if applicable)
Optional but beneficial data includes:
Structural information (if available)
Target antigen details
Known experimental data (e.g., binding affinity, expression levels)
Specific concerns (e.g., aggregation, immunogenicity risks)
👉 Even with limited input data, our AI models can generate meaningful insights, and additional data can further improve prediction depth and accuracy.
What You'll Receive
Our deliverables are designed to provide both deep scientific insight and actionable guidance.
Deliverable
Description
Developability Assessment Report
Comprehensive multi-parameter analysis of antibody candidates
Risk Scoring Dashboard
Visualized ranking and risk profiling
Optimization Recommendations
Sequence-level suggestions for improvement
Candidate Prioritization List
Top candidates with detailed justification
Structural Models
Predicted antibody 3D structures
Experimental Validation Data (Optional)
Wet-lab confirmation of key properties
Our Collaborative Process
At CD ComputaBio, we believe that successful antibody development is built on close collaboration, clear communication, and iterative optimization. Our workflow is designed to seamlessly integrate with your discovery pipeline—whether you are at the early screening stage or advancing preclinical candidates.
Project Initiation & Strategic Alignment
We begin by working closely with your team to understand the scientific goals, project stage, and development challenges.
What we do:
Define project scope (screening, optimization, or full pipeline support)
Review antibody sequences, formats, and target information
Stronger data package for internal and external stakeholders
Why Choose CD ComputaBio?
Your Partner in Developability-Driven Antibody Engineering
Integrated AI + wet-lab platform
Multi-parameter optimization expertise
Fast turnaround and scalable workflows
Proven success in antibody engineering projects
Customized solutions tailored to your pipeline
We don't just evaluate antibodies—we help you build better biologics from the ground up.
Frequently Asked Questions
Partnership
Developability is no longer a downstream concern—it is a strategic advantage when addressed early. With the AbGenesis™ Platform, CD ComputaBio empowers you to predict risks, optimize intelligently, and accelerate antibody development with confidence. By combining advanced AI with deep biological expertise, we help you transform promising candidates into clinically viable therapeutics—faster, safer, and more efficiently. Contact us today to accelerate your target discovery program.
Figure 1. AbGenesis™ Platform.
Figure 2. AI optimization strategies.